STUDY

Humira cleared psoriasis in 80% of people, vs 36% on methotrexate

“Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).” Saurat JH et al. British Journal of Dermatology. November 2008

Saurat JH et al. · British Journal of Dermatology · November 2008

Randomized controlled trialPlaque PsoriasisHumiraMethotrexate
The finding

In a 16-week trial of 271 people with moderate to severe psoriasis, 80% on adalimumab reached a 75% improvement, compared with 36% on methotrexate and 19% on placebo.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized, with a placebo group. A random process decided who got which treatment. Adalimumab is a shot and methotrexate is a pill, so the trial used a placebo group for comparison.
At a glance

Who was studied and for how long

People
271
108 adalimumab, 110 methotrexate, 53 placebo
Length
16 weeks
Main result at week 16
Condition
Moderate to severe plaque psoriasis
Thick, scaly patches
Compared
Adalimumab vs methotrexate vs placebo
Shot vs pill vs dummy
Goal
75% better
Called PASI 75
What they did

How the study worked

271 peoplemoderate to severe plaque psoriasisRANDOMSPLITAdalimumab108 people · shot every other weekMethotrexate110 people · pill once a weekPlacebo53 people · dummyMEASURED ATWeek 16by PASI score271 peoplemoderate to severe plaque psoriasisRANDOMSPLITAdalimumab108 people · shot every other weekMethotrexate110 people · pill once a weekPlacebo53 people · dummyMEASURED ATWeek 16by PASI score
1. Split at random271 people with moderate to severe plaque psoriasis were randomly put in one of three groups.
2. Three treatmentsOne group got adalimumab shots every other week. One took methotrexate pills each week, with the dose raised as needed. One got a placebo.
3. Main goalThe main result was how many people got at least 75% better on the PASI score by week 16.
What they found

The results

AdalimumabMethotrexatePlacebo

At least 75% better (PASI 75)

Share of people reaching the main goal at week 16

Adalimumab
79.6%
Methotrexate
35.5%
Placebo
18.9%
Difference unlikely to be chance (p < 0.001)

Skin completely clear

Share with complete clearance at week 16

Adalimumab
16.7%
Methotrexate
7.3%
Placebo
1.9%
Adalimumab beat both methotrexate and placebo on the main goal, and the gaps were large enough that they are unlikely to be luck. Adalimumab also worked fast. Safety was tracked through week 16.
How much to trust it

Strengths and limits

Strengths

  • Randomized, with placebo and methotrexate comparison groups
  • A clear, widely used main goal (PASI 75)
  • Tested a biologic against the standard older pill

Limits

  • Only 16 weeks of results
  • The adalimumab shot and methotrexate pill were not hidden from patients
  • Methotrexate was capped at 25 mg, which may be lower than some patients receive in practice
  • Does not cover long-term safety
High confidence. A large randomized trial with a clear main result. It covers the first 16 weeks only.
What it means for you

The takeaway

Adalimumab did better

For moderate to severe plaque psoriasis, adalimumab got more people to a 75% improvement than methotrexate in this trial, and more people reached clear skin.

Biologics cost more and need a prescription and screening, such as for infections. Methotrexate is a lower-cost option many people still use. Your dermatologist can help you weigh them.

Pages that cite this study

Read more on Dermapedia

Condition
Plaque Psoriasis
Medication
Humira
Medication
Methotrexate
Compare
Humira vs Methotrexate
Terms in this study

Words worth knowing

PASI 75

At least a 75% improvement in the Psoriasis Area and Severity Index score from the start.

Biologic

A medicine made from living cells that targets a part of the immune system. Adalimumab blocks a protein called TNF.

Placebo

A dummy treatment with no active medicine, used for comparison.

p-value

A measure of how likely a difference this size would show up by chance alone. Below 0.05 is the usual cutoff for "probably real."

Original source

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.

PMID 18047523